Efficacy of aspirin desensitization in nasal polyposis

Clinical and biochemical Aspirin desensitization effectiveness assay in patients with nasal polyposis and aspirin sensitive asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016070728821N1

Enrollment

Registered

2016-08-24

Start date

2016-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasal polyp. Polyp of nasal cavity

Interventions

Intervention 1: Intervention group : Aspirin sensitive nasal polyposis patients will recieve 2 days desensitization protocol in case group, that will be done by Ketrolac nasal drop (1 and 2 drop in ea

Treatment - Drugs

Placebo

Intervention group : Aspirin sensitive nasal polyposis patients will recieve 2 days desensitization protocol in case group, that will be done by Ketrolac nasal drop (1 and 2 drop in each canal with 30

Control group: Aspirin sensitive patients in control group receive starch tablet instead of aspirin.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: chronic rhinosinusitis (CRS) with nasal polyposis patients more than 18 years old that is admitted in allergy clinic. CRS diagnose criteria:(1) 2 or more of symptoms: nasal congestion; pain or pressure of face; post or anterior discharge; loss of smell. (2) Symptoms should stay more than 12 week. CRS with nasal polyposis diagnose will confirm by CT SCAN or endoscopy of sinus. Exclusion criteria: Forced expiratory volume at first second less than 70% in spirometry; gastrointestinal bleeding; pregnancy or breast feeding; Anaphylaxy to Nonsteroidal anti inflammatory drugs (NSAID); Myocardial infarction or stroke in last 6 month and sever liver or kidney disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Quality of life. Timepoint: Before and one month after intervention. Method of measurement: Questiner.;Respiratory function. Timepoint: Before and one month after intervention. Method of measurement: Spirometry.	—

Secondary

Measure	Time frame
Interleukin 4. Timepoint: Before and onemonth after intervention. Method of measurement: Quantitative pg/ml.;Interleukin 5. Timepoint: Before and onemonth after intervention. Method of measurement: Quantitative pg/ml.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegar Mortazavi Mehdiabad

Shahid Beheshti University of Medical Sciences; School of Pharmacy

negmort@yahoo.com; n.mortazavi@sbmu.ac.ir+98 21 8820 0123

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026